Plain-English translation of NCT07080775 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson's Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called XS411CN, which involves transplanting specially developed brain cells directly into your brain through surgery. Researchers want to see if this approach is safe and well-tolerated in people with Parkinson's disease whose current medications are no longer controlling their symptoms effectively. This is an early-stage study, so the main goal is to understand safety before testing whether it actually helps.
Many people with Parkinson's disease find that their medications become less effective over time or cause troubling side effects. This treatment is being developed as a potential new option for those patients who need something beyond what current drugs can offer.
You likely qualify if…
You likely don't qualify if…
If accepted, you would undergo brain surgery in which specialized cells are transplanted into specific areas of your brain using precise navigation technology. After surgery, you would need to take immune-suppressing medications to prevent your body from rejecting the transplanted cells. You would be closely monitored in the hospital for at least 7 days after surgery and have a 28-day safety observation period, during which the research team will watch carefully for any side effects or complications.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China